

BC Cancer news and updates from across the province for Systemic Therapy teams

## Biosimilar Oncology Drugs – Rituximab (Riximyo® & Ruxience®)



Following the implementation of bevacizumab biosimilar in November and trastuzumab biosimilar in February, the Provincial Systemic Therapy Program will soon introduce the third oncology biosimilar, rituximab.

Twenty-four treatment programs will be affected by the implementation of biosimilar rituximab. New patients starting on IV rituximab on or after August 1<sup>st</sup> will receive the biosimilar for rituximab. Please note patients on SC rituximab will continue with the reference biologic product, RITUXAN SC®. Furthermore, patients who started treatment with reference biologic prior to August 1<sup>st</sup> and did not meet the clinical criteria to receive SC rituximab, may continue to receive RITUXAN® for the duration of treatment or until they are suitable to receive SC rituximab.

Information and resources on biosimilar drugs for [health care professionals](#) and [patients](#) are available on the BC Cancer website.

## Rituximab

Affected Treatment Programs	Indication (Refer to protocol for more details)
<a href="#">BMTLPDRIT</a>	Summary for Pre-Emptive riTUXimab Therapy of Epstein-Barr Virus (EBV) Related Post-Transplant Lymphoproliferative Disease
<a href="#">LYBENDR</a>	Treatment of Non-Hodgkin Lymphoma with Bendamustine and riTUXimab
<a href="#">LYCHLRR</a>	Treatment of Indolent B-cell Lymphoma with Chlorambucil and riTUXimab
<a href="#">LYCHOPR</a>	Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISTine, predniSONE and riTUXimab (CHOP-R)
<a href="#">LYCHOPRMTX</a>	Summary for Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and riTUXimab in Diffuse Large B-Cell Lymphoma
<a href="#">LYCLLBENDR</a>	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with Bendamustine and riTUXimab
<a href="#">LYCLLCHLR</a>	Treatment of Chronic Lymphocytic Leukemia with Chlorambucil and riTUXimab
<a href="#">LYCLLCVPR</a>	Treatment of relapsed Chronic Lymphocytic Leukemia using Cyclophosphamide, vinCRISTine, predniSONE and riTUXimab (CVP-R)
<a href="#">LYCLLFBR</a>	Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) with Bendamustine and riTUXimab
<a href="#">LYCLLFLUDR</a>	Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and riTUXimab
<a href="#">LYCODXMR</a>	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, vinCRISTine, DOXOrubicin, Methotrexate, Leucovorin (CODOX-M) and riTUXimab

Affected Treatment Programs	Indication (Refer to protocol for more details)
<a href="#">LYCVPR</a>	Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, vinCRiStine, predniSONE and riTUXimab (CVP-R)
<a href="#">LYEPOCHR</a>	Treatment of Lymphoma with DoseAdjusted Etoposide, DOXOrubicin, vinCRiStine, Cyclophosphamide, predniSONE and riTUXimab with Intrathecal Methotrexate
<a href="#">LYFCR</a>	Treatment of Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia with Fludarabine, Cyclophosphamide and riTUXimab
<a href="#">LYFLUDR</a>	Treatment of Relapsed Indolent Lymphoma with Fludarabine and riTUXimab
<a href="#">LYGDPR</a>	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum with riTUXimab
<a href="#">LYHDMRP</a>	Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and riTUXimab
<a href="#">LYIDELAR</a>	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Using Idelalisib and riTUXimab
<a href="#">LYIVACR</a>	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and riTUXimab
<a href="#">LYRICE</a>	Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin’s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and riTUXimab
<a href="#">LYRITUX</a>	Treatment of Lymphoma with Single Agent riTUXimab
<a href="#">LYRITZ</a>	Palliative Therapy For Lymphoma Using Radioimmunotherapy: riTUXimab-Priming for Ibritumomab 90Y (ZEVALIN®)
<a href="#">LYRMTN</a>	Summary for Maintenance riTUXimab for Indolent Lymphoma
<a href="#">LYVENETOR</a>	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Venetoclax and riTUXimab

## Website Resources and Contact Information

CONTACT INFORMATION	EMAIL
To subscribe or update contact information, please contact:	
Provincial Systemic Therapy Program	<a href="mailto:ProvincialSystemicOffice@bccancer.bc.ca">ProvincialSystemicOffice@bccancer.bc.ca</a>
Systemic Therapy Education Bulletin: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/education-bulletin">http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/education-bulletin</a>	